Idenix Pharmaceuticals, Inc. (IDIX)

Company Overview
Idenix Pharmaceuticals, Inc. is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The company's research and development focus is on the treatment of hepatitis C virus (HCV). In July 2009, the company completed the proof-of-concept clinical trial in treatment-naive HCV genotype I infected patients. In October 2009, it initiated a 14-day dose-ranging phase IIa clinical trial evaluating IDX184 in combination with pegylated interferon and ribavirin in treatment-naive HCV genotype I infected patients. Idenix selected IDX320 as its lead clinical candidate from its protease inhibitor discovery program. Th...
read more


To see the headquarters in Google Street View &trade, drag this yellow guy: over to the red pointer:

Contact Information:

Business Address: 60 Hampshire Street, Cambridge, MA 02139, United States
Mailing Address: -
Phone: 617-995-9800
Fax: 617-995-9801
Website: http//

Company Details:

Symbol: IDIX
SIC: 2834
State location: MA
Sector: -
State of Inc: DE
Employees: 144
Type: -

Key executives:

Name Age Position
Andrea J. Corcoran 56 Advisor
David A. Arkowitz 57 Chief Financial Officer, Principal Accounting Officer and Treasurer
Douglas Mayers M.D. 2018 Exec. VP and Chief Medical Officer
Guy MacDonald 59 Exec. VP of Operations
Jean-Pierre Sommadossi Ph.D. 62 Founder, Chairman, Chief Exec. Officer and Pres